Rewards Outweigh Risk for Long-Term Equity Players: Featured Research on Pier 1 Imports, CarMax, Transocean, Enanta and Aratana
PR Newswire - Mon Dec 22, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pier 1 Imports (NYSE: PIR), CarMax (NYSE: KMX), Transocean (NYSE: RIG), Enanta (NASDAQ: ENTA), and Aratana (NASDAQ: PETX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KMX: 67.61 (-0.15), RIG: 18.77 (-0.37), PIR: 15.33 (-0.11), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06)
Nasdaq stocks posting largest percentage increases
AP - Fri Dec 19, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 34.96 (+0.78), OFLX: 34.45 (unch), INGN: 29.99 (-0.09), PETX: 17.05 (+0.42), HGSH: 4.60 (-0.06), NYNY: 7.89 (+0.32), SNFCA: 5.08 (-0.36)
S&P 500 Falls Just Short of Record Entering Final Weeks of Year
at The Street - Fri Dec 19, 3:06PM CST
The Federal Reserve triggers a three-day rally which sees major indexes jump more than 3% over the past five sessions.
KMX: 67.61 (-0.15), KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), CVX: 113.47 (-0.48), SLB: 87.06 (-0.26), FINL: 22.79 (+0.17), XLE: 80.13 (-0.59)
Stocks at Session Highs as Energy Sector Picks Up Steam
at The Street - Fri Dec 19, 2:04PM CST
Stocks are higher Friday, with the energy sector leading the S&P 500's gains.
KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), FINL: 22.79 (+0.17), SLB: 87.06 (-0.26), KMX: 67.61 (-0.15), APP: 1.06 (+0.01), RHT: 70.92 (+0.47), CVX: 113.47 (-0.48), XLE: 80.13 (-0.59), TNK: 4.74 (+0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 0.91 (+0.01), FATE: 4.90 (+0.23), IMDZ: 34.96 (+0.78), RXII: 1.60 (unch), GLMD: 5.95 (+0.15), TBIO: 2.31 (-0.09), SIM: 10.11 (+0.34), PHMD: 1.46 (-0.03), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), NQ: 4.32 (-0.36), OTIC: 32.26 (+0.65), VHC: 5.98 (-0.19), FINL: 22.79 (+0.17), BBLU: 1.15 (-0.03), TRXC: 2.79 (+0.03), BAS: 7.30 (-0.08), ENRJ: 2.43 (+0.03), TNK: 4.74 (+0.04)
Energy Stocks Lead Market Gains as Crude Oil Prices Bounce
at The Street - Fri Dec 19, 10:11AM CST
Stocks were rising slightly, with energy stocks the leading gainers.
KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), PETX: 17.05 (+0.42), XRX: 14.08 (+0.01), FINL: 22.79 (+0.17), SLB: 87.06 (-0.26), KMX: 67.61 (-0.15), RHT: 70.92 (+0.47), CVX: 113.47 (-0.48), XLE: 80.13 (-0.59)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST
KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)
Aratana up big on canine pain med trial results
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:58AM CST
PETX: 17.05 (+0.42)
Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis
PR Newswire - Thu Dec 18, 3:52PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for companion animals, today announced positive results from its pivotal field study of AT-001 (Grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily oral dose. Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016.
PETX: 17.05 (+0.42)
Aratana Therapeutics Initiates Pivotal Study for AT-003
PR Newswire - Tue Dec 16, 3:28PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the initiation of the pivotal field effectiveness study for AT-003, the company's innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). AT-003 is an extended release injectable formulation of bupivacaine.
PETX: 17.05 (+0.42), PCRX: 92.09 (-1.79)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Aratana Therapeutics to Present at the 2014 Animal & Dental Health Summit
PR Newswire - Fri Dec 05, 11:13AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 2014 Animal & Dental Health Summit, to be held December 11-12, 2014, at the Bank of America Merrill Lynch Conference Center in Boston, MA.
PETX: 17.05 (+0.42)
Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Fri Nov 28, 9:52AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 26th Annual Piper Jaffray Healthcare Conference, to be held December 2-3, 2014, at the New York Palace Hotel in New York.
PETX: 17.05 (+0.42)
Aratana Therapeutics to Present at Jefferies Global Healthcare Conference
PR Newswire - Mon Nov 17, 1:12PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the Jefferies Global Healthcare Conference, to be held November 19-20, 2014, at the Waldorf Hilton Hotel in Aldwych, London.
PETX: 17.05 (+0.42)
Aratana Therapeutics' (PETX) CEO Steven St. Peter on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 1:29PM CST
PETX: 17.05 (+0.42)
Aratana beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 4:11AM CST
KANSAS CITY, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Tuesday reported a third-quarter loss of $10.1 million.
PETX: 17.05 (+0.42)
Notable earnings before Tuesday's open
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:30PM CST
DHI: 24.80 (-0.01), CST: 44.01 (+0.01), INSY: 41.52 (+0.51), QIWI: 20.88 (+0.36), OTIV: 1.71 (unch), PETX: 17.05 (+0.42), SABR: 20.39 (+0.07), ACM: 30.46 (+0.06)
Aratana Therapeutics beats by $0.06
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:23PM CST
PETX: 17.05 (+0.42)